MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, today announces its
financial results for the third quarter ended September 30, 2007.
All dollar amounts referenced herein are in US dollars, unless
otherwise stated.
ART incurred a net loss for the three-month period ended
September 30, 2007 of $2,200,777 or $0.04 per share, compared to
$3,324,441 or $0.07 per share for the three-month period ended
September 30, 2006. For the nine-month period ended September 30,
2007, the net loss was $6,939,854 or $0.12 per share, compared to
$10,109,538 or $0.21 per share, for the nine-month period ended
September 30, 2006.
Third Quarter Highlights:
- ART appointed Mr. Dino DiCamillo to take on responsibility for
direct distribution of the Optix� preclinical imaging system in
North America and Europe, as part of several key additions to the
ART commercialization team, an initiative which will offer improved
service and applications support, as well as a significant gross
margin increase for each system sold.
- ART announced the initiation of a prepurchase and evaluation
process for a SoftScan� optical breast imaging system at the Ville
Marie Medical and Women's Health Center in Montreal, Canada, and
anticipates that it will soon make its first breakthrough sale of
SoftScan in Canada. Other key reference medical accounts are in the
process of being established.
- ART formed a collaboration with the National Research Council
of Canada's Institute for Biological Sciences for the development
of client-oriented diagnostic applications using the Company's
proprietary time domain technology, in the emerging discipline of
molecular imaging.
- ART announced an agreement to develop and conduct clinical
research with the Stanford Breast Imaging Section of Stanford
University to evaluate the effectiveness of the SoftScan optical
breast imaging system in treatment monitoring and diagnosis of
breast cancer.
- ART presented Optix- and Fenestra�-based research at the Joint
Molecular Imaging Conference of the Academy of Molecular Imaging
(AMI) and the Society for Molecular Imaging (SMI), held in Rhode
Island
- ART initiated a process designed to rationalize its operations
and reduce expenses with a focus on commercialization and support
of all of its products.
Post-Quarter Highlights:
- ART has signed an underwriting and agency agreement with a
syndicate of underwriters for the offering of up to 31,250,000
common shares of ART at a price of CAD$0.16, for total gross
proceeds of up to CAD$5,000,000.
- ART has secured a Letter of Purchase Intent from Sunnybrook
Health Sciences Centre for a SoftScan breast imaging system,
engaging the facility in a formal purchasing process.
- ART has been granted a new U.S. patent for optimal selection
of SoftScan optical wavelengths.
Revenues
For the three-month period ended September 30, 2007, revenues
were $267,741, compared to $821,640 for the same period ended
September 30, 2006. Sales resulting from products amounted to
$267,741, compared to $821,640 for the same quarter of last year.
There were no sales resulting from maintenance for the nine-month
period, compared to $164,617 in the same period ended September 30,
2006. Revenues resulting from sales of products for the nine-month
period ended September 30, 2007 amounted to $703,907, compared to
$2,288,251 for the same period of last year. During the quarter
ended September 30, 2007, the Company sold add-ons and Fenestra
products. There were no Optix units sold during that period (1 unit
during the nine-month period ended September 30, 2007) compared to
two units (nine for the nine-month period ended September 30, 2006)
during the same quarter in the previous year. In 2007, the Company
did not perform any upgrades of single-wavelength systems to the
new multiwavelength system. Two systems were upgraded during the
three-month period ended September 30, 2006. Sales from products
include the multi-wavelength Optix system as well as add-ons and
the sales of the Fenestra product. Sales resulting from maintenance
include upgrades of the single-wavelength system to the
multiwavelength system and the sale of demonstration units.
As explained in the past, the Company is in a transition phase
for the distribution of its Optix system. ART is now implementing a
new sales distribution model, comprised of a mix of direct and
indirect sales channels. In August 2007, ART indicated that it has
retained exclusivity for itself with respect to distributing
directly in North America and in Europe. In light of this
transition, the distribution agreement with GE Healthcare for the
distribution of the Optix system is no longer in effect. However,
the Company is still in discussions with GE Healthcare for the
distribution of the Optix system in Asia, and more specifically in
Japan where ART's Fenestra contrast agent product is already
distributed by GE Healthcare Bio-Sciences KK. Through this
distribution model, ART intends to develop a closer rapport with
its customers, in particular with large pharmaceutical companies,
with whom it has established favourable relationships. As part of
its new marketing strategy, ART is in the process of recruiting up
to five sales professionals, combined with in-house application
specialists. This will allow the Company to solidify sales while
providing higher gross margins per system sold. The strategy ART
has adopted has been benchmarked against highly successful sales
programs used by high-end imaging product companies, and validated
through consultations with senior and experienced sales
executives.
Furthermore, ART has developed a commercialization plan to allow
for the sale and support of SoftScan systems in Canada and in
Europe, including the hiring of an experienced executive director
responsible for the effective marketing and sale of SoftScan. In
the third quarter of 2007, ART announced the initiation of a
prepurchase and evaluation process for a SoftScan optical breast
imaging system at the Ville Marie Medical and Women's Health Center
("Ville Marie") in Montreal, Quebec. Ville Marie thus intends to
introduce SoftScan into its future first-line multi-imaging breast
cancer detection and treatment monitoring process, after an
evaluation by its staff of the on-site capabilities of SoftScan and
its seamless integration into the patients' workflow. Following the
close of the third quarter, ART also announced that it had secured
a letter of purchase intent from the Sunnybrook Health Sciences
Centre ("Sunnybrook") in Toronto, for the purchase of a SoftScan
system. Sunnybrook had based its decision on encouraging
preliminary results obtained during an ongoing pilot study at their
facility to determine the role for the SoftScan system in
monitoring response to treatment of breast cancer. These sales
activities reflect the strategy of the Company to establish
reference accounts with facilities and thought leaders that are in
a position to demonstrate the value of the technology from an
economic point of view. This approach is expected to lead the way
for future growth opportunities.
Cost of sales
Cost of sales for the three-month period ended September 30,
2007 was $91,120, compared to $452,020 in the third quarter of
2006. For the nine-month period ended September 30, 2007, cost of
sales was $313,312, compared to $1,457,686 for the nine-month
period ended September 30, 2006. During the three and nine-month
periods ended September 30, 2007, ART generated a gross margin of
66% and 55% respectively from the sales of its products compared to
45% and 42% for the same periods in the previous year. The gross
margin generated on the sales of maintenance was 16% for both the
three and nine-month periods ended September 30, 2006. The increase
of the gross margin, as a percentage of sales, in the three-month
and nine-month periods ended in September 30, 2007 compared to the
same periods of the previous year, is due to the mixed composition
of sales. The sales of Fenestra products represented a higher
proportion of the total sales in the current period of 2007 and
provided a higher margin as a percentage of sales than the sales of
Optix systems. Cost of sales consisted principally of raw
materials, royalties and manufacturing costs.
Operating expenses
The Company's research and development ("R&D") expenditures
for the three-month period ended September 30, 2007, net of
investment tax credits amounted to $1,093,057, compared to
$1,970,493 for the same period ended September 30, 2006. For the
nine-month period ended September 30, 2007, R&D expenditures,
net of investment tax credits, were $3,990,556, compared to
$6,319,605 for the nine-month period ended September 30, 2006. The
R&D expenditures consist principally of the salaries and fringe
benefit expenses of employees involved in R&D projects, the
consultation fees paid for clinical studies, the cost associated
with the preparation and conduct of the clinical studies and of the
cost of prototypes. The decrease in R&D expenditures during the
three-month and the nine-month periods ended September 30, 2007,
compared to the same periods last year, relates to the medical
sector and in particular the SoftScan program, and is mainly due to
lower contract research costs engaged in the current period of 2007
following the Health Canada approval obtained in December 2006 and
the CE marking received for Europe in February 2007. The decrease
of clinical testing expenses incurred in the nine-month period
ended September 30, 2007 compared to the same period of 2006
approximates $2,003,561.
Selling, general, and administrative ("SG&A") expenses for
the three-month period ended September 30, 2007 totaled $1,088,071,
compared to $999,682 for the same period ended September 30, 2006.
For the nine-month period ended September 30, 2007, SG&A
expenses were $3,706,266, compared to $2,979,117 for the nine-month
period ended September 30, 2006. SG&A expenses consist
principally of salaries, professional fees and other costs
associated with marketing activities and intellectual property
maintenance fees. The increase in SG&A expenses during the
three-month and the nine-month periods ended September 30, 2007
compared to the same periods of 2006 mainly results from direct
marketing activities to support the commercialization of the Optix,
SoftScan and Fenestra products.
Net Loss
As a result, the net loss for the three-month period ended
September 30, 2007 was $2,200,777 or $0.04 per share, compared to
$3,324,441 or $0.07 per share for the three-month period ended
September 30, 2006. For the nine-month period ended September 30,
2007, the net loss was $6,939,854 or $0.12 per share, compared to
$10,109,538 or $0.21 per share, for the nine-month period ended
September 30, 2006.
Financial Outlook
On November 13, 2007, the Company has signed an underwriting and
agency agreement with a syndicate of underwriters. Simultaneously,
the Company filed a final prospectus with securities regulatory
authorities for a total offering of up to CAD$5,000,000 at a price
of CAD$0.16 per common share which would result in the issuance of
a total of up to 31,250,000 common shares. The underwriters also
have the option to acquire up to an additional 4,351,875 common
shares at the same issue price of CAD$0.16 per share within 30 days
of the closing of the offering. ART currently anticipates to close
the offering on November 27, 2007. On a pro forma basis, as at
September 30, 2007, considering this financing round, the Company
will have US$6,153,417 of cash (net of financing fees and related
costs) and US$1,834,495 in accounts receivable and investment tax
credits to fund new and ongoing activities. The Company also has an
Optix systems inventory already funded and which could generate
between US$3 million and US$4 million of revenue.
The financial statements, accompanying notes to the financial
statements, and Management's Discussion and Analysis for the
three-month period ended September 30, 2007, will be available
online at www.sedar.com or at www.art.ca. Summary financial tables
are provided below. A detailed list of the risks and uncertainties
affecting the Company can be found in the Management's Discussion
and Analysis.
Conference Call
ART will host a conference call today at 5:00 PM (EDT). The
telephone number to access the conference call is (514) 861-1531
when dialing within the Montreal area, or (877) 667-7766 for the
rest of North America. Outside of North America, please dial (514)
861-1531. A replay of the call will be available until November 22,
2007. To listen to the replay from the Montreal area, please dial
(514) 861-2272, or, (800) 408-3053 for the rest of North America.
From outside of North America, please dial (514) 861-2272. The
access code for the replay is 3241023#.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at www.art.ca
.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Financial Statements (in U.S. dollars)
ART Advanced Research Technologies Inc.
Balance Sheets
(In U.S. dollars)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
September 30, December 31,
2007 2006
--------------------------------------------------------------------------
ASSETS (unaudited) (audited)
Current assets
Cash $544,606 $6,546,936
Term deposit, 3.35%, maturing in
October 2007 150,000 -
Term deposits, 4%, maturing in July 2008 1,103,411 -
Accounts receivable 913,011 625,189
Investment tax credits receivable 921,484 353,583
Inventories 1,987,201 1,715,592
Prepaid expenses 314,645 331,782
--------------------------------------------------------------------------
5,934,358 9,573,082
Property and equipment 574,385 504,426
Patents 2,151,316 1,962,038
Deferred development costs 1,081,109 459,488
--------------------------------------------------------------------------
$9,741,168 $12,499,034
--------------------------------------------------------------------------
--------------------------------------------------------------------------
LIABILITIES
Current liabilities
Credit facility $603,136 $-
Accounts payable and accrued liabilities 2,406,024 3,256,756
Deferred grant 151,769 129,552
Income taxes payable -- 806,751
--------------------------------------------------------------------------
3,160,929 4,193,059
SHAREHOLDERS' EQUITY
Share capital and share purchase warrants 27,953,017 24,126,432
Contributed surplus 3,776,881 3,586,059
Deficit (28,382,900) (21,247,643)
Accumulated other comprehensive income 3,233,241 1,841,127
--------------------------------------------------------------------------
6,580,239 8,305,975
--------------------------------------------------------------------------
$9,741,168 $12,499,034
--------------------------------------------------------------------------
--------------------------------------------------------------------------
ART Advanced Research Technologies Inc.
Shareholders' Equity and Comprehensive Income
(In U.S. dollars)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Common Shares Preferred Shares
------------------------ ------------------
(audited) Number Amount Number Amount
------------------------ ------------------
Balance as at
January 1, 2006 42,664,523 $78,678,625 6,341,982 $5,900,000
Net loss - - - -
Translation adjustment - - - -
--------------------------------------------------------------------------
Comprehensive income - - - -
--------------------------------------------------------------------------
Reduction of stated
capital - (70,585,829) - -
Issue of shares for cash 9,333,400 6,283,708 2,000,000 2,007,043
Issue of shares for
business acquisition 251,058 185,000 - -
Issue of share purchase
warrants - - - -
Share and share purchase
warrant issue expenses - - - -
Stock-based compensation - - - -
Convertible debentures
settlement - - - -
Expired warrants - - - -
Shares to be issued for
business acquisition 162,369 95,262 - -
--------------------------------------------------------------------------
Balance as at December
31, 2006 52,411,350 $14,656,766 8,341,982 $7,907,043
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Shares to be issued as at
December 31, 2006 (162,369) (95,262) - -
Balance as at
January 1, 2007 52,248,981 $14,561,504 8,341,982 $7,907,043
(unaudited)
Net loss - - - -
Translation adjustment - - - -
--------------------------------------------------------------------------
Comprehensive income - - - -
--------------------------------------------------------------------------
Issue of shares for
business acquisition 162,369 95,262 - -
Issue of shares for cash 10,879,242 3,390,696 - -
Issue of share purchase
warrants - - - -
Share and share purchase
warrant issue expenses - - - -
Stock-based compensation - - - -
Expired warrants - - - -
--------------------------------------------------------------------------
Balance as at September
30, 2007 63,290,592 $18,047,462 8,341,982 $7,907,043
--------------------------------------------------------------------------
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Share capital and
Share purchase Equity
Warrants Warrants Component of
--------------------------------------- Convertible
(audited) Number Amount Total Debentures
---------- --------------------------- -----------
Balance as at
January 1, 2006 4,022,817 $2,553,099 $87,131,724 $1,510,467
Net loss - - - -
Translation
adjustment - - - -
--------------------------------------------------------------------------
Comprehensive
income - - - -
--------------------------------------------------------------------------
Reduction of stated
capital - - (70,585,829) -
Issue of shares for
cash - - 8,290,751 -
Issue of shares for
business acquisition - - 185,000 -
Issue of share
purchase warrants 678,891 146,648 146,648 -
Share and share
purchase warrant
issue expenses - - - -
Stock-based
compensation - - - -
Convertible
debentures
settlement - - - (1,510,467)
Expired warrants (743,185) (1,137,124) (1,137,124) -
Shares to be issued
for business
acquisition - - 95,262 -
--------------------------------------------------------------------------
Balance as at
December 31, 2006 3,958,523 $1,562,623 $24,126,432 $-
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Shares to be issued
as at December 31,
2006 - - (95,262) -
Balance as at
January 1, 2007 3,958,523 $1,562,623 $24,031,170 $-
(unaudited)
Net loss - - - -
Translation
adjustment - - - -
--------------------------------------------------------------------------
Comprehensive
income - - - -
--------------------------------------------------------------------------
Issue of shares for
business acquisition - - 95,262 -
Issue of shares for
cash - - 3,390,696 -
Issue of share
purchase warrants 2,175,841 497,303 497,303 -
Share and share
purchase warrant
issue expenses - - - -
Stock-based
compensation - - - -
Expired warrants (373,336) (61,414) (61,414) -
--------------------------------------------------------------------------
Balance as at
September 30, 2007 5,761,028 $1,998,512 $27,953,017 $-
--------------------------------------------------------------------------
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Accumulated
Other
Contributed Comprehensive
(audited) Surplus Deficit Income Total
------------ -------------- -------------- ----------
Balance as at
January 1, 2006 $721,051 $(82,033,557) $2,039,128 $9,368,813
Net loss - (8,754,767) - (8,754,767)
Translation
adjustment - - (198,001) (198,001)
--------------------------------------------------------------------------
Comprehensive
income - (8,754,767) (198,001) (8,952,768)
--------------------------------------------------------------------------
Reduction of
stated capital - 70,585,829 - -
Issue of shares
for cash - - - 8,290,751
Issue of shares
for business
acquisition - - - 185,000
Issue of share
purchase warrants - - - 146,648
Share and share
purchase warrant
issue expenses - (1,045,148) - (1,045,148)
Stock-based
compensation 268,206 - - 268,206
Convertible
debentures
settlement 1,459,678 - - (50,789)
Expired
warrants 1,137,124 - - -
Shares to be
issued for
business
acquisition - - - 95,262
--------------------------------------------------------------------------
Balance as at
December 31,
2006 $3,586,059 $(21,247,643) $1,841,127 $8,305,975
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Shares to be
issued as at
December 31,
2006 - - - (95,262)
Balance as at
January 1, 2007 $3,586,059 $(21,247,643) $1,841,127 $8,210,713
(unaudited)
Net loss - (6,939,854) - (6,939,854)
Translation
adjustment - - 1,392,114 1,392,114
--------------------------------------------------------------------------
Comprehensive
income - (6,939,854) 1,392,114 (5,547,740)
--------------------------------------------------------------------------
Issue of shares
for business
acquisition - - - 95,262
Issue of shares
for cash - - - 3,390,696
Issue of share
purchase warrants - - - 497,303
Share and share
purchase warrant
issue expenses - (195,403) - (195,403)
Stock-based
compensation 129,408 - - 129,408
Expired
warrants 61,414 - - -
--------------------------------------------------------------------------
Balance as at
September 30,
2007 $3,776,881 $(28,382,900) $3,233,241 $6,580,239
--------------------------------------------------------------------------
--------------------------------------------------------------------------
ART Advanced Research Technologies Inc.
Operations
(In U.S. dollars)
(unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Three-month Nine-month
periods ended periods ended
September 30 September 30
2007 2006 2007 2006
--------------------------------------------------------------------------
Sales
Products $267,741 $821,640 $703,907 $2,288,251
Maintenance - - - 164,617
--------------------------------------------------------------------------
267,741 821,640 703,907 2,452,868
--------------------------------------------------------------------------
Cost of sales
Products 91,120 452,020 313,312 1,319,851
Maintenance - - - 137,835
--------------------------------------------------------------------------
91,120 452,020 313,312 1,457,686
--------------------------------------------------------------------------
Gross margin 176,621 369,620 390,595 995,182
--------------------------------------------------------------------------
Operating expenses
Research and
development,
net of
investment
tax credits 1,093,057 1,970,493 3,990,556 6,319,605
Selling,
general and
administrative 1,088,071 999,682 3,706,266 2,979,117
Severance and
related costs - 361,118 - 361,118
Amortization 85,301 68,594 259,989 213,194
--------------------------------------------------------------------------
2,266,429 3,399,887 7,956,811 9,873,034
--------------------------------------------------------------------------
Operating loss 2,089,808 3,030,267 7,566,216 8,877,852
Financial
expenses 110,969 294,174 184,943 1,231,686
--------------------------------------------------------------------------
Loss from
operations
before income
taxes 2,200,777 3,324,441 7,751,159 10,109,538
Current income
taxes - - (811,305) -
--------------------------------------------------------------------------
Net loss $2,200,777 $3,324,441 $6,939,854 $10,109,538
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Basic and
diluted net loss
per share $0.04 $0.07 $0.12 $0.21
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Basic and
diluted weighted
average number
of common shares
outstanding 63,290,592 52,248,981 60,148,336 47,518,138
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Number of common
shares
outstanding,
end of period 63,290,592 52,248,981 63,290,592 52,248,981
--------------------------------------------------------------------------
--------------------------------------------------------------------------
ART Advanced Research Technologies Inc.
Cash Flows
(In U.S. dollars)
(Unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Three-month Nine-month
periods ended periods ended
September 30 September 30
2007 2006 2007 2006
--------------------------------------------------------------------------
OPERATING
ACTIVITIES
Net loss $(2,200,777) $(3,324,441) $(6,939,854) $(10,109,538)
Items not
affecting
cash
Amortization 85,301 68,594 259,988 213,194
Stock-based
compensation 28,274 69,299 129,274 210,754
Interest on
convertible
debentures - 259,272 - 926,232
Net changes
in working
capital items
Accounts
receivable (90,352) 91,640 (229,936) 313,266
Investment
tax credits
receivable (178,725) 433,686 (461,078) 363,941
Inventories 19,805 114,878 19,866 18,927
Prepaid
expenses 55,568 38,161 70,703 (14,833)
Accounts
payable and
accrued
liabilities (165,761) (364,808) (1,096,831) (383,748)
Deferred
grant - - - 40,190
Income taxes
payable - - (811,304) -
--------------------------------------------------------------------------
Cash flows
from
operating
activities (2,446,667) (2,613,719) (9,059,172) (8,421,615)
--------------------------------------------------------------------------
INVESTING
ACTIVITIES
Business
acquisition - 148,201 - (452,455)
Short-term
investments 2,017,154 (1,017,631) (742,305) 3,271,107
Property and
equipment (16,629) - (112,780) (181,733)
Deferred
development
costs (251,829) (25,696) (493,635) (57,028)
--------------------------------------------------------------------------
Cash flows
from
investing
activities 1,748,696 (895,126) (1,348,720) 2,579,891
--------------------------------------------------------------------------
FINANCING
ACTIVITIES
Credit
facility - - 546,398 -
Repayment of
senior
convertible
debentures - (625,000) - (1,875,000)
Issue of
convertible
preferred
shares - - - 2,031,361
Issue of
common shares
and share
purchase
warrant - - 3,887,999 6,283,707
Equity issue
expenses - - (195,403) (909,956)
--------------------------------------------------------------------------
Cash flows
from
financing
activities - (625,000) 4,238,994 5,530,112
Effect of
foreign
currency
translation
adjustments 59,985 24,306 316,568 208,663
--------------------------------------------------------------------------
59,985 (600,694) 4,555,562 5,738,775
--------------------------------------------------------------------------
Net decrease
in cash and
cash
equivalents (637,986) (4,109,539) (5,852,330) (102,949)
Cash and cash
equivalents,
beginning of
period 1,332,592 8,865,732 6,546,936 4,859,142
--------------------------------------------------------------------------
Cash and cash
equivalents,
end of period $694,606 $4,756,193 $694,606 $4,756,193
--------------------------------------------------------------------------
--------------------------------------------------------------------------
CASH AND CASH
EQUIVALENTS
Cash $544,606 $4,750,377 $544,606 $4,750,377
Term deposit 150,000 - 150,000 -
Commercial
paper - 5,816 - 5,816
--------------------------------------------------------------------------
$694,606 $ 4,756,193 $694,606 $4,756,193
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Supplemental
disclosure of
cash flow
information
Interest
received $69,912 $31,193 $93,344 $ 112,699
Interest paid 17,315 93,853 44,193 340,689
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024